Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jose Miguel Cuevas Sanz"'
Autor:
Sergio Vázquez, Jose Miguel Cuevas Sanz, A. González-del-Alba, Alvaro Pinto, Jacobo Muñoz del Toro, Ángela García García-Porrero, Ángel Francisco Zazo Rodríguez, Javier Puente, Eduardo Useros Rodríguez, Núria Sala-González, María José Méndez-Vidal
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to co
Autor:
Maria Jose Mendez, Jose Miguel Cuevas Sanz, Arancha Gonzalez del Alba, Angela Garcia, Sergio Vazquez-Estevez, Jacobo Muñoz del Toro, Angel Sánchez, Pedro Ruiz, Núria Sala, Javier Puente, Alvaro Pinto
Publikováno v:
Journal of Clinical Oncology. 35:276-276
276 Background: Abiraterone acetate + prednisone (AA) and cabazitaxel (CB) have shown an improvement in overall survival after Docetaxel (DOC) in (mCRPC)1,2. There is little evidence about the optimal sequencing treatment in prospective trials. In th
Autor:
Javier Puente, María José Méndez-Vidal, Núria Sala, Jacobo Muñoz del Toro, Alvaro Pinto, Angela Garcia, Jose Miguel Cuevas Sanz, Pedro Ruiz, Aranzazu Gonzalez del Alba, Sergio Vazquez-Estevez, Angel Sánchez
Publikováno v:
Journal of Clinical Oncology. 35:227-227
227 Background: Recently treatment options for mCRPC have increased considerably. It remains unclear if there is any predictive factor to recognize which patients (pts) could obtain the most benefit in second line (2L) mCRPC. Recent data have been pu
Autor:
Rocío García Domínguez, Enrique Gonzalez-Billalabeitia, María José Méndez-Vidal, Laura Basterrechea, Antonio López Jiménez, Alvaro Pinto, Carmen Molins, Núria Sala, Raquel Luque, Angel Rodriguez Sanchez, Pablo Borrega, Jose Miguel Cuevas Sanz, Guillermo Crespo, Montserrat Domenech, Sergio Vazquez-Estevez, Javier Puente, Josep Guma, Pedro Ruiz, Aranzazu Gonzalez del Alba, Miguel Ángel Cabrera Suárez
Publikováno v:
Journal of Clinical Oncology. 34:229-229
229 Background: Novel agents, such as abiraterone (A), cabazitaxel (CZ), and enzalutamide are currently available for the treatment of docetaxel (D)-treated metastatic castration resistant prostate cancer (mCRPC). The sequencing approach following D
Autor:
José Marcelo Galbis-Caravajal, Maria José Artes-Martínez, Jose Miguel Cuevas-Sanz, María Navarro-Hervás, Gabriel Sales-Badía
Publikováno v:
Cirugía Española. 84:235-236
Autor:
Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, María José Méndez-Vidal, Alvaro Pinto, Ángel Rodríguez, José Miguel Cuevas Sanz, Jacobo Rodrigo Muñoz del Toro, Eduardo Useros Rodríguez, Ángela García García-Porrero, Sergio Vázquez
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns,
Externí odkaz:
https://doaj.org/article/7a49a1a1be274ce3b87d79bfb68cdf6a